Artivion (NYSE:AORT) Price Target Cut to $42.00 by Analysts at Citizens Jmp

Artivion (NYSE:AORT) had its price target decreased by research analysts at Citizens Jmp from $48.00 to $42.00 in a research note issued to investors on Friday, Benzinga reports. The firm presently has a “market outperform” rating on the stock. Citizens Jmp‘s price target suggests a potential upside of 96.05% from the stock’s previous close.

Other equities analysts have also recently issued reports about the company. Citigroup reissued a “market outperform” rating on shares of Artivion in a report on Tuesday, July 21st. Canaccord Genuity Group set a $30.00 price target on Artivion in a research note on Friday. Wall Street Zen cut Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Jefferies Financial Group assumed coverage on Artivion in a research note on Tuesday, October 20th. They set a “buy” rating and a $31.00 price objective for the company. Finally, Weiss Ratings cut Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Artivion currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.57.

Artivion Price Performance

NYSE AORT traded down $3.91 on Friday, reaching $21.42. The company’s stock had a trading volume of 238,201 shares, compared to its average volume of 596,020. The firm has a market cap of $1.04 billion, a PE ratio of -307.81 and a beta of 1.31. The business has a 50-day moving average price of $23.67 and a 200 day moving average price of $29.09. Artivion has a 52 week low of $19.16 and a 52 week high of $48.25. The company has a current ratio of 3.47, a quick ratio of 2.51 and a debt-to-equity ratio of 0.82.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.14. The firm had revenue of $123.79 million during the quarter, compared to analyst estimates of $120.97 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. Sell-side analysts expect that Artivion will post 0.45 EPS for the current year.

Insiders Place Their Bets

In other news, SVP Jean F. Holloway sold 977 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total value of $27,834.73. Following the completion of the sale, the senior vice president directly owned 184,118 shares in the company, valued at approximately $5,245,521.82. This trade represents a 0.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Andrew M. Green sold 11,480 shares of Artivion stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $24.97, for a total value of $286,655.60. Following the completion of the transaction, the senior vice president directly owned 40,160 shares of the company’s stock, valued at $1,002,795.20. This represents a 22.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 90,460 shares of company stock valued at $2,557,366. 6.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Artivion

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AORT. BlackRock Inc. bought a new position in shares of Artivion in the second quarter worth about $149,965,000. Wellington Management Group LLP lifted its position in shares of Artivion by 9.0% during the second quarter. Wellington Management Group LLP now owns 1,260,279 shares of the company’s stock worth $28,318,000 after purchasing an additional 103,592 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Artivion by 4.8% during the first quarter. Dimensional Fund Advisors LP now owns 1,027,575 shares of the company’s stock valued at $37,626,000 after purchasing an additional 46,738 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Artivion by 0.8% during the first quarter. Bank of America Corp DE now owns 522,515 shares of the company’s stock valued at $19,135,000 after purchasing an additional 3,980 shares during the last quarter. Finally, Principal Financial Group Inc. grew its stake in shares of Artivion by 8.7% during the first quarter. Principal Financial Group Inc. now owns 261,370 shares of the company’s stock valued at $9,571,000 after purchasing an additional 20,921 shares during the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Key Stories Impacting Artivion

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Q3 revenue rose 9% year over year to $123.8 million, exceeding analyst estimates of about $121 million. Artivion also projected 2026 revenue of $484 million to $492 million, signaling continued growth. Artivion Reports Third Quarter 2026 Financial Results
• Positive Sentiment: The company is preparing to launch its NEXUS aortic product in January 2027, a potential growth catalyst as it expands its product portfolio. Artivion outlines 2026 revenue and NEXUS launch
• Negative Sentiment: Profitability was weaker: Artivion reported a GAAP net loss of $7.9 million, while adjusted EPS of $0.08 fell short of Zacks’ $0.11 consensus and compared with $0.16 a year earlier. Adjusted EBITDA declined 8% to $22.5 million, which may temper the positive revenue news. Artivion lags Q3 earnings estimates
• Negative Sentiment: Canaccord lowered its price target on AORT to $30, a sign of reduced analyst expectations that could add pressure despite the company’s revenue growth. Canaccord lowers Artivion price target

About Artivion

Artivion, Inc (NYSE: AORT) is a medical device and biotechnology company focused on developing and commercializing products used in cardiac and vascular surgery. Its portfolio includes implantable devices, surgical sealants, and human tissue products designed to treat diseases of the heart, aorta, and peripheral blood vessels.

The company’s products include On-X mechanical heart valves, aortic and vascular grafts, BioGlue surgical adhesive, and stent graft systems for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in reconstructive procedures.

Artivion was formerly known as CryoLife, a company founded in 1984, and adopted the Artivion name in 2021 to reflect its broader focus on aortic and cardiac care.